<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202189</url>
  </required_header>
  <id_info>
    <org_study_id>DMED-892-05</org_study_id>
    <nct_id>NCT00202189</nct_id>
  </id_info>
  <brief_title>Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Acute Effects of Inhaled Corticosteroids on Dynamic Airway Function During Rest and Exercise in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human and animal studies have shown that inhaled corticosteroids (ICS) decrease airway blood&#xD;
      flow . This effect is immediate (within 30 minutes), transient (lasting 90 minutes), and in&#xD;
      animal studies independent of gene expression. In COPD patients, decrease in bronchial blood&#xD;
      flow may also decrease mucosal edema, airway resistance and improve small airway function. If&#xD;
      such an effect exists, then we should be able to measure improvements in airway conductance&#xD;
      and reduce lung hyperinflation, which would have salutary effects on dyspnea and exercise&#xD;
      endurance.&#xD;
&#xD;
      To our knowledge, no study has examined the immediate effect of ICS on small airway function&#xD;
      in COPD. The purpose of this study is to examine the effects of nebulized Pulmicort on small&#xD;
      airway function (spirometry, plethysmographic lung volumes, airways resistance, closing&#xD;
      volume, partial flow-volume loop analysis) and exercise endurance in patients with moderate&#xD;
      to severe COPD.&#xD;
&#xD;
      HYPOTHESIS&#xD;
&#xD;
        1. Nebulized ICS will immediately improve airway function compared with placebo (nebulized&#xD;
           saline).&#xD;
&#xD;
        2. Enhanced lung emptying and reduced operating lung volumes during rest and exercise&#xD;
           following ICS therapy will translate acutely into clinically important reductions in&#xD;
           exertional dyspnea and improvements in exercise endurance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single site, pilot, randomized, double-blinded, placebo-controlled, cross-over&#xD;
      study that will be conducted at this centre. Subjects will be required to complete four (4)&#xD;
      visits to the laboratory over a one-month period.&#xD;
&#xD;
      At Visit 1, subjects who meet all study inclusion and exclusion criteria, will have a full&#xD;
      set of pulmonary function tests (PFT) done and complete a symptom-limited incremental cycle&#xD;
      exercise test. At Visit 2, subjects will have a partial set of pulmonary function tests (PFT)&#xD;
      done and complete a symptom-limited constant load cycle exercise test. On the third and&#xD;
      fourth visit subjects will be randomized to treatment with either nebulized saline or&#xD;
      nebulized PulmicortÂ® in a double blinded, cross-over design, subsequent to which they will&#xD;
      have their PFT's and symptom limited constant load exercise testing done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endurance time</measure>
    <time_frame>60 minutes post-inhalation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dyspnea</measure>
    <time_frame>60-minutes post-inhalation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution (0.9% NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FEV1 less than/equal to 70 % predicted, FEV1/FVC ratio less than/equal to 70%, and FRC&#xD;
             greater than/equal to 120 % predicted&#xD;
&#xD;
          -  Moderate to severe chronic activity-related dyspnea (modified Baseline Dyspnea Index&#xD;
             focal score less than/equal to 6)&#xD;
&#xD;
          -  Clinically stable as defined by no changes in medication dosage or frequency of&#xD;
             administration with no exacerbations or hospital admissions in the preceding four&#xD;
             weeks&#xD;
&#xD;
          -  Males or females greater than 40 years of age;&#xD;
&#xD;
          -  A cigarette smoking history of at least 20 pack-years&#xD;
&#xD;
          -  Able to perform all study procedures and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of asthma, atopy or nasal polyps&#xD;
&#xD;
          -  Recent history of cardiovascular disease (&lt; 1 year) or other significant disease that&#xD;
             could contribute to dyspnea or exercise limitation&#xD;
&#xD;
          -  Oxygen saturation less than 80% during exercise on room air&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis E O'Donnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University-Respiratory Investigation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory Investigation Unit</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 12, 2008</last_update_submitted>
  <last_update_submitted_qc>August 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Denis O'Donnell</name_title>
    <organization>Queen's University</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Pulmicort</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Chronic</keyword>
  <keyword>Obstructive</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Disease</keyword>
  <keyword>Exercise</keyword>
  <keyword>Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

